Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cefotaxime
Drug ID BADD_D00390
Description Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).
Indications and Usage Used to treat gonorrhoea, meningitis, and severe infections including infections of the kidney (pyelonephritis) and urinary system. Also used before an operation to prevent infection after surgery.
Marketing Status Prescription; Discontinued
ATC Code J01DD01
DrugBank ID DB00493
KEGG ID D07647
MeSH ID D002439
PubChem ID 5742673
TTD Drug ID D0D1HA
NDC Product Code 0143-9933; 0143-9930; 0143-9935; 0143-9931
Synonyms Cefotaxime | Cephotaxim | Cefotaxim | Biosint | Cefotaxime Sodium | Sodium, Cefotaxime | Cefradil | Taporin | Fotexina | HR-756 | HR 756 | HR756 | Kendrick | Ru-24756 | Ru 24756 | Ru24756 | Benaxima | Claforan | Primafen | Klaforan
Chemical Information
Molecular Formula C16H17N5O7S2
CAS Registry Number 63527-52-6
SMILES CC(=O)OCC1=C(N2C(C(C2=O)NC(=O)C(=NOC)C3=CSC(=N3)N)SC1)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vaginal inflammation21.14.02.001--
Vasculitis24.05.02.001; 10.02.02.0060.000213%
Vomiting07.01.07.0030.000532%
White blood cell count decreased13.01.06.0120.000213%
Tubulointerstitial nephritis20.05.02.002--Not Available
Histiocytosis haematophagic10.02.01.042; 01.05.01.0150.000213%Not Available
Acute generalised exanthematous pustulosis23.03.10.002; 12.03.01.0050.000532%Not Available
Red blood cell sedimentation rate increased13.01.03.0010.000213%Not Available
Cardiopulmonary failure22.02.06.004; 02.05.01.0040.000056%Not Available
Haemorrhage24.07.01.002--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Induration08.01.03.020--Not Available
Hepatic enzyme increased13.03.01.0190.000426%Not Available
Ill-defined disorder08.01.03.049--Not Available
Renal impairment20.01.03.010--Not Available
Exfoliative rash23.03.07.0060.000213%Not Available
Liver injury12.01.02.003; 09.01.07.022--Not Available
Traumatic liver injury12.01.02.008; 09.01.08.010--Not Available
Acute kidney injury20.01.03.0160.000426%
Drug reaction with eosinophilia and systemic symptoms23.03.05.005; 10.01.01.0210.001384%Not Available
Candida infection11.03.03.021--
Nosocomial infection11.07.02.0060.000167%Not Available
Transferrin saturation decreased13.11.01.0510.000319%Not Available
Clostridium difficile infection11.02.02.0090.000639%Not Available
The 4th Page    First    Pre   4    Total 4 Pages